Product logins

Find logins to all Clarivate products below.


Biosimilars | Access & Reimbursement | Global | 2016

The regulatory and market access environment for biosimilars is constantly evolving. For a company seeking to develop a biosimilar for multiple markets, staying ahead of the similarities and differences between each country can be a major challenge. The Access & Reimbursement Overview allows rapid assessment of key parameters including the scope of biosimilars guidelines, choice of reference product, pricing mechanisms for biosimilars, and strategies in place to drive uptake across the United States, EU5, Japan, Australia, Canada, and the leading growth markets.

Related Market Assessment Reports

Report
Biosimilars – Access & Reimbursement – Payer Insights Landscape (US/EU)
Biosimilar regulations and guidance have been defined, at least in draft form, in most the world’s leading pharmaceutical markets. In many cases, biosimilar guidance is based on that of the EMA,…
Report
Biosimilars – Corporate Strategies – Biosimilar Developer Strategies
The commercial opportunity available to biosimilars manufacturers is undeniably large, but developing a strategy that will capture a profitable share of the market is challenging. Unlike the…
Report
Biosimilars – Corporate Strategies – Reference Brand Developer Strategies
The commercial opportunity available to biosimilars manufacturers is undeniably large, but developing a strategy that will capture a profitable share of the market is challenging. Unlike the…
Report
Biosimilars – Emerging Biosimilars – Emerging Biosimilars Landscape
The Emerging Biosimilars Landscape offers extensive coverage of the global biosimilars development landscape. We track over 853 currently available and novel biosimilar products, detailing…
Report
Biosimilars – Forecast – Neurology
In 2024, sales of branded MAb biologics in neurology exceeded $12 billion in the major pharmaceutical markets (United States, EU5, and Japan). Throughout our 2024-2034 forecast period, the…